Literature DB >> 12694082

Impact of carbohydrate and fat intake on weight-reducing efficacy of orlistat.

A Ullrich1, J Erdmann, J Margraf, V Schusdziarra.   

Abstract

BACKGROUND: Orlistat treatment of obesity results in a poor long-term weight loss (< 5%) in about 30% of patients. AIM: Total energy and macronutrient intake were examined to assess the effect of a change in eating habits on weight loss.
METHODS: Sixty-two patients consumed a hypocaloric diet, together with orlistat (3 x 120 mg/day), for 72 weeks, with a maximal fat allowance of 30% of the energy intake. At regular intervals, food diaries were recorded.
RESULTS: Fifty-six patients completed the study and lost 8.5 +/- 0.88 kg (P < 0.001). Energy intake was approximately 1500 kcal/day during the entire study period. In three sub-groups established according to weight loss (1, < 5%; 2, > 5% and < 10%; 3, > 10%), fat intake was within the recommended range in all groups during the first 6 months, but thereafter only in group 3. All groups increased their carbohydrate consumption, with the greatest increase in group 1, which could account for the rapid regain of initially lost body weight in this group.
CONCLUSION: At the beginning of a weight management programme in conjunction with orlistat, a low fat intake is advised for an efficient reduction in body weight. Subsequently, in patients with poor long-term weight loss, dietary recommendations must also consider carbohydrate restriction to ensure an adequate hypocaloric diet.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12694082     DOI: 10.1046/j.1365-2036.2003.01530.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

1.  Successful weight loss and maintenance in everyday clinical practice with an individually tailored change of eating habits on the basis of food energy density.

Authors:  Volker Schusdziarra; Margit Hausmann; Corina Wiedemann; Julie Hess; Cornelia Barth; Stefan Wagenpfeil; Johannes Erdmann
Journal:  Eur J Nutr       Date:  2010-12-01       Impact factor: 5.614

2.  Predictors of weight loss and maintenance in patients treated with antiobesity drugs.

Authors:  Federica Guaraldi; Uberto Pagotto; Renato Pasquali
Journal:  Diabetes Metab Syndr Obes       Date:  2011-06-20       Impact factor: 3.168

3.  Tackling obesity: new therapeutic agents for assisted weight loss.

Authors:  Jg Karam; Si McFarlane
Journal:  Diabetes Metab Syndr Obes       Date:  2010-04-26       Impact factor: 3.168

4.  Hafnia alvei HA4597 Strain Reduces Food Intake and Body Weight Gain and Improves Body Composition, Glucose, and Lipid Metabolism in a Mouse Model of Hyperphagic Obesity.

Authors:  Nicolas Lucas; Romain Legrand; Camille Deroissart; Manon Dominique; Saïda Azhar; Marie-Anne Le Solliec; Fatima Léon; Jean-Claude do Rego; Pierre Déchelotte; Sergueï O Fetissov; Grégory Lambert
Journal:  Microorganisms       Date:  2019-12-23

5.  Food intake and plasma ghrelin response during potato-, rice- and pasta-rich test meals.

Authors:  Johannes Erdmann; Yvonne Hebeisen; Florian Lippl; Stefan Wagenpfeil; Volker Schusdziarra
Journal:  Eur J Nutr       Date:  2007-05-11       Impact factor: 4.865

Review 6.  Precision medicine in adult and pediatric obesity: a clinical perspective.

Authors:  Eric M Bomberg; Justin R Ryder; Richard C Brundage; Robert J Straka; Claudia K Fox; Amy C Gross; Megan M Oberle; Carolyn T Bramante; Shalamar D Sibley; Aaron S Kelly
Journal:  Ther Adv Endocrinol Metab       Date:  2019-07-27       Impact factor: 3.565

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.